Gowling WLG has advised on the transaction MEDI8897 is a monoclonal antibody for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus…
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur’s agreement to develop and commercialise MEDI8897.
